Effect of perindopril or leucine on physical performance in older people with sarcopenia: the LACE randomized controlled trial
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Background: This trial aimed to determine the efficacy of leucine and/or perindopril in improving physical function in older people with sarcopenia. Methods: Placebo‐controlled, parallel group, double‐blind, randomized two‐by‐two factorial trial. We recruited adults aged ≥ 70 years with sarcopenia, defined as low gait speed (<0.8 m/s on 4 m walk) and/or low handgrip strength (women < 20 kg, men < 30 kg) plus low muscle mass (using sex and body mass index category‐specific thresholds derived from normative UK BioBank data) from 14 UK centres. Eligible participants were randomized to perindopril 4 mg or placebo, and to oral leucine powder 2.5 g or placebo thrice daily. The primary outcome was the between‐group difference in the short physical performance battery (SPPB) score over 12‐month follow‐up by repeated‐measures mixed models. Results were combined with existing systematic reviews using random‐effects meta‐analysis to derive summary estimates of treatment efficacy. Results: We screened 320 people and randomized 145 participants compared with an original target of 440 participants. For perindopril [n = 73, mean age 79 (SD 6), female sex 39 (53%), mean SPPB 7.1 (SD 2.3)] versus no perindopril [n = 72, mean age 79 (SD 6), female sex 39 (54%), mean SPPB 6.9 (SD 2.4)], median adherence to perindopril was lower (76% vs. 96%; P < 0.001). Perindopril did not improve the primary outcome [adjusted treatment effect −0.1 points (95%CI −1.2 to 1.0), P = 0.89]. No significant treatment benefit was seen for any secondary outcome including muscle mass [adjusted treatment effect −0.4 kg (95%CI −1.1 to 0.3), P = 0.27]. More adverse events occurred in the perindopril group (218 vs. 165), but falls rates were similar. For leucine [n = 72, mean age 78 (SD 6), female sex 38 (53%), mean SPPB 7.0 (SD 2.1)] versus no leucine [n = 72, mean age 79 (SD 6), female sex 40 (55%), mean SPPB 7.0 (SD 2.5)], median adherence was the same in both groups (76% vs. 76%; P = 0.99). Leucine did not improve the primary outcome [adjusted treatment effect 0.1 point (95%CI −1.0 to 1.1), P = 0.90]. No significant treatment benefit was seen for any secondary outcome including muscle mass [adjusted treatment effect −0.3 kg (95%CI −1.0 to 0.4), P = 0.47]. Meta‐analysis of angiotensin converting enzyme inhibitor/angiotensin receptor blocker trials showed no clinically important treatment effect for the SPPB [between‐group difference −0.1 points (95%CI −0.4 to 0.2)]. Conclusions: Neither perindopril nor leucine improved physical performance or muscle mass in this trial; meta‐analysis did not find evidence of efficacy of either ACE inhibitors or leucine as treatments to improve physical performance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gait speed and survival in older adults.
Studenski, S. (2011) · JAMA · doi:10.1001/jama.2010.1923 · Cited by 4,558 · cited 1×
“19 The handgrip cut-offs used were derived from a population-based observational study and were found to be optimal to discriminate participants with mobility limitation.”
Cruz-Jentoft, A. J., & Sayer, A. A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31138-9 · Cited by 3,905
Self-citationCruz-Jentoft, A. J., Landi, F., Schneider, S. M., Zuniga, C., Arai, H., Boirie, Y., Chen, L.-K., Fielding, R. A., Martin, F. C., Michel, J.-P., et al. (2014) · Age and Ageing · doi:10.1093/ageing/afu115 · Cited by 1,963
Lauretani, F., Russo, C. R., Bandinelli, S., Bartali, B., Cavazzini, C., Di Iorio, A., Corsi, A. M., Rantanen, T., Guralnik, J. M., & Ferrucci, L. (2003) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00246.2003 · Cited by 1,946 · cited 1×
“The handgrip cut-offs used were derived from a population-based observational study and were found to be optimal to discriminate participants with mobility limitation.(20)”
Yeung, S. S. Y., Reijnierse, E. M., Pham, V. K., Trappenburg, M. C., Lim, W. K., Meskers, C. G. M., & Maier, A. B. (2019) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12411 · Cited by 1,115
Bauer, J. M., Verlaan, S., Bautmans, I., Brandt, K., Donini, L. M., Maggio, M., McMurdo, M. E. T., Mets, T., Seal, C., Wijers, S. L., et al. (2015) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2015.05.021 · Cited by 670 · cited 1×
“Some previous interventions have combined leucine with additional protein or amino acid supplements and with other nutrients such as vitamin D.(17,40) Some, but not all, of these trials have suggested improvements to muscle mass, although the effect on muscle strength has been less convincing.”
BackgroundTieland, M., Dirks, M. L., van der Zwaluw, N., Verdijk, L. B., van de Rest, O., de Groot, L. C. P. G. M., & van Loon, L. J. C. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.05.020 · Cited by 556
Sergi, G., De Rui, M., Veronese, N., Bolzetta, F., Berton, L., Carraro, S., Bano, G., Coin, A., Manzato, E., & Perissinotto, E. (2015) · Clinical Nutrition · doi:10.1016/j.clnu.2014.07.010 · Cited by 467
Onder, G., Penninx, B. W., Balkrishnan, R., Fried, L. P., Chaves, P. H., Williamson, J., Carter, C., Bari, M. D., Guralnik, J. M., & Pahor, M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08024-8 · Cited by 339 · cited 13×
“Observational data show that older people taking angiotensin converting enzyme inhibitors (ACEi) have better preserved walk speed over a three-year period than those not taking ACEi [12].”
InfluentialLiu, P., Hao, Q., Hai, S., Wang, H., Cao, L., & Dong, B. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.04.007 · Cited by 331
Exercise interventions for the prevention and treatment of sarcopenia. A systematic umbrella review.
Beckwée, D., Delaere, A., Aelbrecht, S., Baert, V., Beaudart, C., Bruyere, O., de Saint-Hubert, M., & Bautmans, I. (2019) · The Journal of nutrition, health and aging · doi:10.1007/s12603-019-1196-8 · Cited by 330 · cited 1×
“7 Resistance training is the intervention with the most evidence to prevent or reverse sarcopenia 6,8,9 ; however, not all older people with sarcopenia are either willing or able to un-dertake resistance training.”
Kyle, U. G., Genton, L., Hans, D., & Pichard, C. (2003) · Clinical Nutrition · doi:10.1016/s0261-5614(03)00048-7 · Cited by 248 · cited 2×
“These cut-offs were derived from normative bioimpedance data from healthy middle aged adults in the UK BioBank study 22 Total body fat-free mass index cut-offs for the fi fth percentile were used and converted to equivalent appendicular skeletal muscle mass values using values from Kyle et al .”
Sumukadas, D., Witham, M. D., Struthers, A. D., & McMurdo, M. E. T. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.061339 · Cited by 246 · cited 3×
“However, the perindopril dose used has previously demonstrated improvement in six-minute walk distance and quality of life in older people with functional impairment [31].”
BackgroundMethodSelf-citationPharmacologic Options for the Treatment of Sarcopenia
Morley, J. E. (2016) · Calcified Tissue International · doi:10.1007/s00223-015-0022-5 · Cited by 225 · cited 1×
“11 The relative contributions of these pathologies remain to be fully delineated.”
Effects of Leucine Administration in Sarcopenia: A Randomized and Placebo-controlled Clinical Trial
Martínez-Arnau, F. M., Fonfría-Vivas, R., Buigues, C., Castillo, Y., Molina, P., Hoogland, A. J., van Doesburg, F., Pruimboom, L., Fernández-Garrido, J., & Cauli, O. (2020) · Nutrients · doi:10.3390/nu12040932 · Cited by 120
Cited by
Sayer, A. A., Cooper, R., Arai, H., Cawthon, P. M., Ntsama Essomba, M.-J., Fielding, R. A., Grounds, M. D., Witham, M. D., & Cruz-Jentoft, A. J. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00550-w · Cited by 380
Self-citationCurrent and investigational medications for the treatment of sarcopenia
Rolland, Y., Dray, C., Vellas, B., & Barreto, P. D. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155597 · Cited by 195
Chen, Y. C., Chen, W.-C., Liu, C.-W., Huang, W.-Y., Lu, I., Lin, C. W., Huang, R. Y., Chen, J. S., & Huang, C. H. (2023) · European Review of Aging and Physical Activity · doi:10.1186/s11556-023-00333-4 · Cited by 34
Fielding, R. A., Dao, M. M., Cannon, K., Desvarieux, M., Miller, S. S., Gimness, M. P., Brandon, D. M., Villareal, D. T., Bruyere, O., Bautmans, I., et al. (2025) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13750 · Cited by 16
Metadata
- Authors
- The LACE study group, Achison, M., Adamson, S., Akpan, A., Aspray, T., Avenell, A., Band, M. M., Bashir, T., Burton, L. A., Cvoro, V., Donnan, P. T., Duncan, G. W., George, J., Gordon, A. L., Gregson, C. L., Hapca, A., Henderson, E., Hume, C., Jackson, T. A., Kemp, P., Kerr, S., Kilgour, A., Lyell, V., Masud, T., McKenzie, A., McKenzie, E., Patel, H., Pilvinyte, K., Roberts, H. C., Rossios, C., Sayer, A. A., Smith, K. T., Soiza, R. L., Steves, C. J., Struthers, A. D., Sumukadas, D., Tiwari, D., Whitney, J., & Witham, M. D.
- Venue
- Journal of Cachexia, Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2022-02-16
- Volume
- 13
- Issue
- 2
- Pages
- 858-871
- ISSN
- 2190-5991 (ISSN-L)
- 2190-6009
- OpenAlex
- W4213065184
- Cited by
- 51
- References
- 15
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.